GlaxoSmithKline News and Research

RSS

Decision Resources forecasts the launch of four new agents to treat DMD by 2021

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that interviewed experts unanimously identify a disease-modifying therapy as the highest unmet need in the treatment of Duchenne muscular dystrophy (DMD).

8 Jun 2012

FDA approves XenoPort, GSK’s Horizant ER tablets for management of PHN

GlaxoSmithKline plc (GSK) and XenoPort, Inc. announced today that the United States (US) Food and Drug Administration (FDA) has approved Horizant (gabapentin enacarbil) Extended-Release Tablets for the management of postherpetic neuralgia (PHN) in adults.

7 Jun 2012

Dengue fever vaccine 'may be in sight,' Reuters reports

Reuters reports on efforts to develop a vaccine for dengue fever, writing that "victory over ... the intensely painful 'breakbone fever' ... may be in sight." Paris-based firm Sanofi "hopes for positive results in September from a key trial among children in Thailand that would set it on course to market a shot in 2015, which would prevent an estimated 100 million cases of dengue infection each year," the news service writes.

7 Jun 2012

$6.4 million awarded to investigate mechanisms of allergy tolerance generated by Circassia’s ToleroMune Treatment

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that the United States’ National Institutes of Health (NIH) has awarded a $6.4 million grant to Professor Mark Larché of McMaster University, Canada, to study mechanisms of tolerance developed by patients treated with Circassia’s Toleromune® allergy therapy.

7 Jun 2012

WIN Symposium to take place in Paris from June 28-29

On June 28 and 29, academic thought leaders and high-ranking officers from pharma, biotech and information technology companies will gather in Paris at the 4th WIN Symposium to present and discuss breakthroughs that will bring personalized cancer medicine to the next phase.

7 Jun 2012

New data from OncoMed’s OMP-59R5 Phase I study on advanced solid tumors

OncoMed Pharmaceuticals, Inc., a privately held, clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor initiating cells, today highlighted new data presented this afternoon in a poster discussion session at the Annual Meeting of the American Society for Clinical Oncology (ASCO) in Chicago, IL.

4 Jun 2012

UH CNRCS students achieve significant milestones in cancer therapy research

Four University of Houston (UH) students are well on their way to emerging cancer research careers upon achieving significant milestones this spring in their work toward new therapies for prostate and breast cancer.

2 Jun 2012

Al Jazeera business program examines fight against malaria

Al Jazeera's "Counting the Cost" program on Saturday focused on the fight against malaria and the "business behind its treatment and prevention." According to the program, progress against malaria "is being threatened in these tough economic times. There is a $3 billion shortfall in funding for malaria treatment and prevention."

30 May 2012

Large survey of genetic variation offers insights into human diseases

A large survey of human genetic variation, published today in the online version of the journal Science, shows that rare genetic variants are not so rare after all and offers insights into human diseases.

19 May 2012

Dabrafenib drug shrinks tumors in patients with melanoma brain metastases

An experimental drug targeting a common mutation in melanoma successfully shrank tumors that spread to the brain in nine out of 10 patients in part of an international phase I clinical trial report in the May 18 issue of The Lancet.

18 May 2012

Researchers identify cellular mechanism associated with tinnitus

Researchers in the University of Leicester's Department of Cell Physiology and Pharmacology have identified a cellular mechanism that could underlie the development of tinnitus following exposure to loud noises. The discovery could lead to novel tinnitus treatments, and investigations into potential drugs to prevent tinnitus are currently underway.

10 May 2012

Guardian examines launch of GAVI-sponsored immunization campaign in Ghana

Ghana's recent "rollout of the rotavirus vaccine and, to much acclaim, a new vaccine against pneumococcal infections, makes it the first country in sub-Saharan African to introduce two new vaccines at the same time," the Guardian reports.

5 May 2012

NPS first quarter net loss increases to $10.6 million

NPS Pharmaceuticals, Inc., a specialty pharmaceutical company developing orphan therapeutics for rare gastrointestinal and endocrine disorders, today reported its results for the first quarter of 2012.

4 May 2012

XenoPort first quarter revenues increase to $10.4 million

XenoPort, Inc. announced today its financial results for the first quarter ended March 31, 2012. Revenues for the quarter were $10.4 million, compared to $0.4 million for the same period in 2011.

3 May 2012

Ligand first quarter total revenues increase to $5.6 million

Ligand Pharmaceuticals Incorporated today reported financial results for the first quarter ended March 31, 2012, and provided an operating forecast and program updates.

3 May 2012

Guardian, Malaria Consortium hold experts' roundtable discussion on World Malaria Day

The Guardian, in association with Malaria Consortium, hosted a roundtable discussion on World Malaria Day, during which participants heard about progress in the fight against the disease in certain countries and discussed how "the burden of malaria is still high and spending on the disease is inadequate," the Guardian reports.

27 Apr 2012

GSK receives FDA approval for Votrient to treat advanced soft tissue sarcoma

The U.S. Food and Drug Administration today approved Votrient (pazopanib) to treat patients with advanced soft tissue sarcoma who have previously received chemotherapy. Soft tissue sarcoma is a cancer that begins in the muscle, fat, fibrous tissue, and other tissues.

27 Apr 2012

Allied Healthcare increases stake in Coridon to over 44%

Allied Healthcare Group (ASX: AHZ) announced today that post the recent capital raising it has invested a further $1 million into Coridon, increasing its holding in the company to 44.4%. Allied has increased its investment in Coridon as the Company progresses towards its Phase I study for a herpes vaccine and makes further progress on its HPV therapeutic vaccine program.

26 Apr 2012

GSK, Epizyme and Constellation to develop next generation of epigenetic drugs for cancer

Scientific insights that expand on the teachings of Mendel, Watson and Crick, and underpinnings of the Human Genome Project are moving drug companies along the path to development of new medicines based on deeper insights into how factors other than the genetic code influence health and disease. That's the topic of the cover story in the current edition of Chemical & Engineering News (C&EN), the weekly newsmagazine of the American Chemical Society (ACS), the world's largest scientific society.

19 Apr 2012

Impax announces data from IPX066 Phase III study on Parkinson's

Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc., today announced that data from the ASCEND-PD Phase III clinical study involving IPX066 will be presented in a Platform Presentation at the 64th Annual Meeting of the American Academy of Neurology in New Orleans, Louisiana, held from April 21 to April 28.

19 Apr 2012